On March 3, 2026, the U.S. Food and Drug Administration announced it had issued 30 warning letters to telehealth companies for making what the agency called "false or misleading claims" about compounded GLP-1 products on their websites. It was the second major enforcement wave in six months — and a clear signal that the FDA views misleading GLP-1 marketing as a top enforcement priority.
If you're using a telehealth platform for weight loss medication, or considering one, this matters to you. Here's what happened, why it happened, and what it means for consumers trying to make informed decisions about their care.
What the FDA Actually Said
FDA Commissioner Marty Makary framed the action bluntly: the agency is paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms, and taking swift action. He acknowledged that compounded drugs serve a legitimate purpose — overcoming shortages or meeting unique patient needs — but drew a firm line at using compounding to circumvent the FDA approval process.
The 30 warning letters were part of a broader crackdown that began in September 2025. According to the FDA, the agency has sent thousands of warning letters to pharmaceutical and telehealth firms over the past six months — more than had been sent over the entire preceding decade. That's a dramatic acceleration by any measure.
The Two Main Violations
The warning letters focused on two categories of misleading marketing:
1. Implying Equivalence With FDA-Approved Drugs
Many telehealth companies were marketing their compounded GLP-1 products in ways that suggested they were the same as — or interchangeable with — FDA-approved medications like Wegovy, Ozempic, Mounjaro, and Zepbound. Some websites used brand-name imagery, referenced the same active ingredients without proper context, or made claims about safety and effectiveness that only FDA-approved drugs are permitted to make.
The distinction matters. Compounded medications are prepared by pharmacies to meet specific patient needs, but the FDA does not review their safety, effectiveness, or manufacturing quality before they reach patients. They are not the same as generic drugs, which do go through an FDA approval process.
2. Obscuring Who Actually Makes the Medication
The second major violation involved telehealth companies placing their own brand name on product labels or marketing materials in ways that implied they were the manufacturer or compounder. In reality, these companies are technology platforms that connect patients with prescribers and pharmacies — they don't compound drugs themselves. The FDA considers this kind of branding false or misleading because it obscures the actual source of the medication.
Which Companies Were Named?
The FDA identified the 30 companies in publicly available warning letters. Reporting from STAT News and other outlets confirmed that the named companies include Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, GoodGirlRx, Lovely Meds, Hello Cake, and MEDVi, among others. Most are small to midsize digital telehealth providers that expanded rapidly to meet demand for GLP-1 weight loss therapies when brand-name supplies were constrained.
Notably, larger established digital health companies like Ro and Hims & Hers were not among the 30 companies that received warning letters in this round — though Hims & Hers faces a separate legal challenge from Novo Nordisk over compounded oral semaglutide.
STAT News also reported that among the more than 70 telehealth companies warned by the FDA in the preceding six months, at least 30% had publicly stated affiliations with just four nationwide medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra. This suggests that the telehealth GLP-1 market has a more concentrated prescribing infrastructure than the large number of consumer-facing brands might suggest.
Context: Why This Is Happening Now
Several converging factors explain the timing of this enforcement wave:
The GLP-1 shortage is over. The original rationale for widespread compounding — that FDA-approved GLP-1 medications were in short supply — has largely evaporated. Both Novo Nordisk and Eli Lilly have stated that their products are in full supply nationwide. The FDA's notice period for large-scale compounding facilities ended in May 2025, meaning the agency can now take enforcement action against compounders that were previously operating under shortage exemptions.
Consumer demand remains enormous. Demand for GLP-1 weight loss medications continues to grow, and the price gap between brand-name drugs (often $1,000+ per month without insurance) and compounded alternatives ($150–$400 per month through telehealth) creates strong financial incentives on both sides of the transaction.
The regulatory framework is catching up. Telehealth prescribing of GLP-1 medications expanded faster than the regulatory infrastructure designed to oversee it. The FDA's current posture reflects an agency that is now actively trying to close that gap.
What This Means for You as a Consumer
If you're currently using a telehealth platform for GLP-1 medication, the FDA's actions don't necessarily mean your provider is unsafe or illegitimate. But they do mean you should be asking better questions.
Questions to Ask Your Telehealth Provider
- Is my medication FDA-approved or compounded? You have the right to know this, and a legitimate provider will answer clearly.
- If compounded, which pharmacy is preparing it? You should be able to verify that the compounding pharmacy is licensed and in good standing with your state board of pharmacy.
- Is the compounding pharmacy a 503A or 503B facility? 503B outsourcing facilities are subject to more FDA oversight than traditional 503A compounding pharmacies.
- Has this company received any FDA warning letters? Warning letters are public record. You can search for them on the FDA's website.
- What does follow-up care look like? A provider that prescribes and disappears is a red flag regardless of the medication type.
Red Flags vs. Green Flags
Red Flags
The platform implies its product is "the same as" Wegovy or Zepbound. Compounded medications contain similar active ingredients but are not the same product. Any provider suggesting otherwise is doing exactly what the FDA is cracking down on.
You can't identify who compounded your medication. If the telehealth company's brand is on the vial and there's no clear information about the compounding pharmacy, that's a transparency problem.
There's no meaningful medical evaluation. Reporting from WISH-TV highlighted one consumer who received a prescription within 20 minutes without ever speaking to a doctor. An asynchronous intake form alone is not the same as a medical evaluation — and it may not meet prescribing standards in every state.
The pricing seems impossibly low. Compounded medications cost less than brand-name drugs, but there's a floor below which quality becomes questionable. Extremely low prices may indicate cut corners in sourcing or preparation.
Green Flags
Clear labeling of what's compounded vs. FDA-approved. Trustworthy platforms distinguish between the two and explain the difference honestly.
Transparent pharmacy sourcing. You can verify the compounding pharmacy independently through state licensing databases.
Ongoing clinical follow-up. The platform provides structured check-ins during dose titration and beyond — not just at the point of sale.
FDA-compliant marketing language. The website does not use brand-name drug imagery for compounded products or make safety/efficacy claims that belong exclusively to FDA-approved medications.
The Bigger Picture: FDA Enforcement Direction
The March 2026 letters are part of a clear enforcement trajectory. The FDA has signaled that it views the GLP-1 telehealth market as requiring sustained oversight, not one-time correction. Companies were given 15 business days to correct violations, and the agency stated that failure to do so could result in seizure or injunction without further notice.
For consumers, the practical takeaway is that the telehealth landscape for GLP-1 medications is actively evolving. Providers that were operating six months ago may have changed their practices, their product sourcing, or their regulatory status. Checking in on your provider's current standing — not just their reputation from when you signed up — is reasonable and prudent.
The FDA also expanded its enforcement beyond just telehealth firms. Warning letters have been issued to pharmaceutical manufacturers, compounding pharmacies, and other players in the supply chain. This is not a targeted campaign against telehealth as a category — it's a broader effort to clean up marketing practices across the entire GLP-1 ecosystem.
How to Verify a Telehealth Provider
If you want to check whether your telehealth GLP-1 provider has received an FDA warning letter, or if you want to verify their legitimacy before signing up, here are practical steps:
Search the FDA warning letter database. The FDA publishes all warning letters on its website. You can search by company name at fda.gov/warning-letters.
Verify prescriber licensing. Every state medical board maintains a searchable database of licensed physicians and nurse practitioners. If a telehealth platform won't tell you who your prescriber is or what state they're licensed in, that's a problem.
Check the compounding pharmacy. State boards of pharmacy maintain public databases of licensed pharmacies. The FDA also maintains a list of registered 503B outsourcing facilities. Cross-referencing your medication's source against these databases takes minutes and provides meaningful assurance.
Look for clinical transparency. Does the platform publish information about its clinical protocols? Does it describe its approach to dose titration, side effect management, and contraindication screening? Platforms that treat these as competitive advantages rather than secrets are generally more trustworthy.
The Bottom Line
The FDA's March 2026 warning letters represent a meaningful shift in how the agency is approaching the telehealth GLP-1 market. The enforcement focus is on misleading marketing — companies that blur the line between compounded and FDA-approved products, or obscure who is actually making the medication.
As a consumer, you don't need to panic. But you do need to be informed. Ask questions, verify claims, and understand what you're putting in your body. The rapid growth of telehealth GLP-1 prescribing has created genuine access benefits for millions of people — and the regulatory framework is now working to ensure those benefits come with appropriate transparency and accountability.